Oligosaccharide and Probiotic Composition for Insulin Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solutions for improving insulin sensitivity and reducing insulin resistance, particularly in infants born preterm or with intra-uterine growth restriction, pregnant women with gestational diabetes, and individuals with type II diabetes, are ineffective and difficult to comply with, with existing nutritional interventions showing marginal or controversial results.
Innovation Solution
A composition combining specific oligosaccharides, such as lacto-N-neotetraose and lacto-N-tetraose, with long-chain polyunsaturated fatty acids like arachidonic acid and docosahexaenoic acid, and probiotics like Bifidobacterium lactis, is used to enhance insulin sensitivity and reduce insulin resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary and lifestyle changes are implemented to improve insulin sensitivity, then insulin sensitivity improves, but compliance is difficult and not followed by most patients
Solution Approach 1:
The patent changes the biochemical parameters of the diet by introducing specific oligosaccharides (lacto-N-neotetraose, lacto-N-tetraose), long-chain polyunsaturated fatty acids (arachidonic acid, docosahexaenoic acid), and probiotics. These parameter changes in composition lead to improved insulin sensitivity without requiring complex lifestyle modifications, thus resolving the contradiction between improving insulin sensitivity and maintaining compliance.
2Reliability
If existing nutritional interventions are used to improve insulin sensitivity, then some improvement is achieved, but results are marginal or controversial
Solution Approach 1:
The patent employs a composite nutritional intervention combining three specific components: specific oligosaccharides (lacto-N-neotetraose, lacto-N-tetraose), long-chain polyunsaturated fatty acids (arachidonic acid, docosahexaenoic acid), and probiotics. This composite approach synergistically improves insulin sensitivity more effectively than single-nutrient interventions, resolving the contradiction between achieving improvement and ensuring marginal or controversial results.
3Reliability
If insulin treatment is administered to treat type II diabetes, then blood glucose control improves, but the disease progression rate is not significantly reduced
Solution Approach 1:
The patent introduces specific oligosaccharides, long-chain polyunsaturated fatty acids, and probiotics as intermediary substances that modulate the body's response to insulin and glucose. These intermediaries improve insulin sensitivity and glucose metabolism, providing an additional mechanism that complements insulin treatment and significantly reduces disease progression, thereby resolving the contradiction between blood glucose control and disease progression reduction.
Data Source
AI summary
The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one of lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT), at least one N-acetylated oligosaccharide different from LNnT and LNT, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in increasing insulin sensitivity and/or reducing insulin resistance. This composition optionally further comprises 2′-fucosyllactose (FL). This composition is particularly adapted for use in infants who were born preterm and/or who experienced IUGR, in pregnant women suffering from gestational diabetes and in children, adolescents, and adults suffering from insulin resistance and/or type II diabetes.